169 related articles for article (PubMed ID: 24751368)
1. Coxsackievirus A16 encephalitis during obinutuzumab therapy, Belgium, 2013.
Eyckmans T; Wollants E; Janssens A; Schoemans H; Lagrou K; Wauters J; Maertens J
Emerg Infect Dis; 2014 May; 20(5):913-5. PubMed ID: 24751368
[No Abstract] [Full Text] [Related]
2. Disseminated Enteroviral Infection Associated with Obinutuzumab.
Dendle C; Gilbertson M; Korman TM; Golder V; Morand E; Opat S
Emerg Infect Dis; 2015 Sep; 21(9):1661-3. PubMed ID: 26291712
[TBL] [Abstract][Full Text] [Related]
3. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
[TBL] [Abstract][Full Text] [Related]
4. Disseminated enterovirus infection in a patient treated with obinutuzumab.
McNeil T; Hannah R; Hui CH; Qiao M
J Med Virol; 2022 Feb; 94(2):439-441. PubMed ID: 34590740
[No Abstract] [Full Text] [Related]
5. Update on enterovirus infections in infants and children.
Modlin JF
Adv Pediatr Infect Dis; 1996; 12():155-80. PubMed ID: 9033978
[No Abstract] [Full Text] [Related]
6. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.
Grisariu S; Vaxman I; Gatt M; Elias S; Avni B; Arad A; Pasvolsky O; Raanani P; Paltiel O
Hematol Oncol; 2017 Dec; 35(4):591-598. PubMed ID: 27734521
[TBL] [Abstract][Full Text] [Related]
7. Fatal case of enterovirus 71 infection and rituximab therapy, france, 2012.
Kassab S; Saghi T; Boyer A; Lafon ME; Gruson D; Lina B; Fleury H; Schuffenecker I
Emerg Infect Dis; 2013 Aug; 19(8):1345-7. PubMed ID: 23880543
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Phillips T; Brunvand M; Chen AI; Essell J; Chiappella A; Diefenbach C; Cheng J; Ramies D; Hirata J; Morschhauser F; Flinn IW
Am J Hematol; 2022 Jan; 97(1):E24-E27. PubMed ID: 34731510
[No Abstract] [Full Text] [Related]
9. The use of obinutuzumab in chronic lymphocytic leukemia.
Wierda W
Clin Adv Hematol Oncol; 2014 Jun; 12(6):395-7. PubMed ID: 25003571
[No Abstract] [Full Text] [Related]
10. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells.
Fujimura T; Yamashita-Kashima Y; Kawasaki N; Yoshiura S; Harada N; Yoshimura Y
Mol Cancer Ther; 2021 Jun; 20(6):1133-1141. PubMed ID: 33850006
[TBL] [Abstract][Full Text] [Related]
12. Enteroviral encephalitis in a patient with a marginal zone lymphomatreated with rituximab.
Schilthuizen C; Berenschot HW; Levin MD
Neth J Med; 2010 May; 68(5):221-3. PubMed ID: 20508271
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab for the treatment of indolent lymphoma.
Edelmann J; Gribben JG
Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
[TBL] [Abstract][Full Text] [Related]
14. Detection and typing of enteroviruses from CSF specimens from patients diagnosed with meningitis/encephalitis.
Tavakoli NP; Wang H; Nattanmai S; Dupuis M; Fusco H; Hull R
J Clin Virol; 2008 Oct; 43(2):207-11. PubMed ID: 18692435
[TBL] [Abstract][Full Text] [Related]
15. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Cartron G; Hourcade-Potelleret F; Morschhauser F; Salles G; Wenger M; Truppel-Hartmann A; Carlile DJ
Haematologica; 2016 Feb; 101(2):226-34. PubMed ID: 26659915
[TBL] [Abstract][Full Text] [Related]
16. [Lethal enterovirus myocarditis associated with rituximab and chemotherapy for follicular lymphoma].
Alonso JJ; Cánovas A; Rubio G
Med Clin (Barc); 2013 Nov; 141(10):459-60. PubMed ID: 23622890
[No Abstract] [Full Text] [Related]
17. Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature.
Lupia T; Corcione S; Staffilano E; Bosio R; Curtoni A; Busca A; De Rosa FG
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541221
[No Abstract] [Full Text] [Related]
18. Case report: Novel treatment regimen for
Chetty K; Cheng I; Kaliakatsos M; Gonzalez-Granado LI; Klapsa D; Martin J; Bamford A; Breuer J; Booth C
Front Immunol; 2022; 13():930031. PubMed ID: 36177038
[TBL] [Abstract][Full Text] [Related]
19. Atypical enterovirus encephalitis causing behavioral changes and autism-like clinical manifestations: case report.
Akcakaya NH; Tekturk P; Cagatay A; Tur EK; Yapici Z
Acta Neurol Belg; 2016 Dec; 116(4):679-681. PubMed ID: 26895551
[No Abstract] [Full Text] [Related]
20. Obinutuzumab: first global approval.
Cameron F; McCormack PL
Drugs; 2014 Jan; 74(1):147-54. PubMed ID: 24338113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
